| Trial name or title |
Afterload reduction therapy for late anthracycline cardiotoxicity: a pediatric oncology group cancer control study |
| Methods |
Randomised, double‐blinded, phase III trial to compare the effectiveness of enalapril with a placebo in treating heart damage in people who received anthracycline chemotherapy for childhood cancer |
| Participants |
People with histologically diagnosed childhood malignancy who had prior anthracycline therapy and echocardiographic evidence of reduced fractional shortening, reduced contractility, or increased afterload, or any combination of these. At least 6 months oncologic disease‐free. At least 8 years old at study entry and less than 22 years at diagnosis. At least 1 year since prior cumulative anthracycline therapy of at least 200 mg/m² |
| Interventions |
Enalapril maleate and placebo |
| Outcomes |
Body surface area‐adjusted left ventricular mass, ventricular function, quality of life |
| Starting date |
15 August 1997 |
| Contact information |
Stephen Lipshultz, James P. Wilmot Cancer Center |
| Notes |
On the ongoing‐trial website there is a note about the recruitment status: completed. However, we found no publication of this trial. One of the review authors (LK) learned from contacts in the US that this trial has as yet not been executed |
